{
    "nct_id": "NCT06502691",
    "official_title": "[18F]FTT Positron Emission Tomography (PET) in Patients With Metastatic Breast Cancer",
    "inclusion_criteria": "* Patients must have histologically confirmed invasive breast cancer with metastatic disease\n* Patients must be candidates for treatment with PARP inhibitor as a single agent or for PARP inhibitor in combination with an ICI per treating physician discretion\n* Patients must have evaluable disease or at least one measurable lesion that can be assessed at baseline by CT (or magnetic resonance imaging [MRI]) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Age >= 18 years\n* Karnofsky performance status (KPS) >= 50% or Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Archival tissue (formalin-fixed paraffin-embedded [FFPE]) from at least one metastatic site biopsy should be available prior to study enrollment; if archival tissue is not available, then a metastatic site biopsy will be required during the study screening period\n* Patient must be willing to proceed with an on-treatment biopsy of metastatic site if an on-treatment [18F]FTT PET will be performed (at 12 ± 4 weeks after starting PARP inhibitor ± ICI treatment)\n* For women of childbearing potential, a negative serum pregnancy test is required within 7 days prior to [18F]FTT PET imaging on day 1. For women who obtain on-treatment (12-week) [18F]FTT imaging, a negative serum pregnancy test will be required within 7 days prior to [18F]FTT PET imaging\n* Men and women of reproductive potential need to agree to employ two highly effective and acceptable forms of contraception throughout their participation in the study\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations\n* Ability to understand and the willingness to sign a written informed consent document. Informed consent must be provided prior to any study specific procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with prior myelodysplastic syndrome or acute myeloid leukemia due to rare risk associated with PARP inhibitor therapy\n* Pregnant or breastfeeding women\n* Patient with a known hypersensitivity to the proposed PARP inhibitor product\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of PARP inhibitor therapy (per investigator's discretion)",
    "miscellaneous_criteria": ""
}